Image

Nebulised 3% Hypertonic Saline Versus 0.9% Saline for Treating Patients Hospitalized With Acute Bronchiolitis

Recruiting
5 - 24 years of age
Both
Phase N/A

Powered by AI

Overview

Bronchiolitis is an acute viral infection of the lower respiratory tract. It is most commonly caused by respiratory syncytial virus (RSV). Only supportive therapy, including suctioning nasal secretions, water-electrolyte balance maintenance, and oxygen supplementation when needed, is recommended. The inhalation of 3% hypertonic saline is not recommended in bronchiolitis management. However, a recently published meta-analysis revealed that the inhalation of hypertonic saline can reduce the risk of hospitalisation for outpatients with bronchiolitis, while resulting in a shorter length of hospital stay and reduced severity of respiratory distress for inpatients, although the evidence is of low certainty.

The aim of the study is to assess the efficacy of nebulised hypertonic saline for the treatment of children hospitalised with bronchiolitis.

Eligibility

Inclusion Criteria:

  1. Children admitted to the hospital with the clinical diagnosis of acute bronchiolitis, which is defined as an apparent viral respiratory tract infection associated with airway obstruction manifested by at least one of following symptoms:
    • Tachypnoea (WHO definition).
    • Increased respiratory effort manifested as follows:
      1. Nasal flaring;
      2. Grunting;
      3. Use of accessory muscles;
      4. Intercostal and/or subcostal chest wall retractions;
      5. Apnoe.
    • Crackles and/or wheezing.
  2. Aged 5 weeks - 24 months old.
  3. A caregiver must provide written informed consent.

Exclusion Criteria:

  1. Infants hospitalised with severe bronchiolitis (requiring mechanical ventilation or intensive care, or oxygen saturation < 85% on room air).
  2. History of prematurity (gestational age <34 weeks).
  3. Diagnosis of a clinically significant chronic disease (cardiac, respiratory, neuromuscular, or metabolic).
  4. Immunodeficiency.
  5. Gastro-oesophageal reflux.
  6. Diagnosis or suspicion of asthma.
  7. Inhaling a nebulised 3% hypertonic saline solution within 12 hours before enrolment.
  8. Inhaling bronchodilators within 24 hours before enrolment.
  9. Inhaling steroids within 24 hours before enrolment.
  10. Systemic steroid therapy in the preceding 2 weeks.

Study details

Bronchiolitis

NCT06069336

Szpital im. Św. Jadwigi Śląskiej

28 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.